INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) Files An 8-K Results of Operations and Financial Condition

INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) Files An 8-K Results of Operations and Financial Condition
Item 2.02 –Results of Operations and Financial Condition

Story continues below

On July 17, 2018, the Company issued a press release reporting our preliminary expected financial results for the second quarter ended June 30, 2018. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 – Financial Statements and Exhibits

(d) Exhibits

Exhibit No.

Description

Press release issued July 17, 2018, reporting preliminary expected financial results for the second quarter ended June 30, 2018


INNOVUS PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 ex99-1.htm PRESS RELEASE Blueprint   Exhibit 99.1     Innovus Pharmaceuticals Reports Preliminary Q2 2018 Sales Revenue of $6.6 million to $6.8 million   Preliminary Quarterly Revenue Increase of 47-51% and Comparable 2017 Second Quarter Increase of 330-340% and Fiscal Year 2018 Net Revenue Annual Guidance Adjusted Upwards to at Least $22 Million   SAN DIEGO,…
To view the full exhibit click here

About INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV)

Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe.

An ad to help with our costs
/* */ // AST – IMS - [MarketExclusive_ROS]